The global biomarkers market was valued at US$ 82.35 billion in 2023 and is projected to reach US$ 366.6 billion by 2034, growing at a compound annual growth rate (CAGR) of 14.54% from 2024 to 2034. This growth is driven by the increasing incidence of chronic diseases, advancements in research and development, and rising investments in the sector.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5322
Favorable Government Policies Dominate North America
North America continues to lead the biomarkers market due to state-of-the-art research infrastructure and strong government support. The US Food and Drug Administration (FDA) has been pivotal in integrating biomarkers into medical product development and approval processes. This initiative accelerates the development of new therapeutics, making the region a hub for biomarkers-related research.
The Canadian government has also made substantial contributions through initiatives like the Canadian Health Measures Survey (CHMS), which monitors human biomonitoring data and collaborates with Health Canada and the Public Health Agency of Canada. Such programs facilitate the collection of vital data that supports biomarker research and development. Together, these favorable policies create a conducive environment for the market’s growth in North America.
Rising Incidences of Chronic Disorders Drive Asia-Pacific Growth
Asia-Pacific is forecasted to be the fastest-growing region for biomarkers in the coming years. The rapid rise in chronic disorders, along with increasing investments in research and development, is expected to fuel the demand for biomarkers in this region. The growing prevalence of diseases like cancer, immunological disorders, and neurological diseases is expected to propel the biomarkers market.
In countries like China, India, and Japan, the aging population and the high incidence of chronic diseases are creating a pressing need for biomarkers in disease diagnosis and drug discovery. For example, China alone has over 15 million people aged 60 and older living with dementia, while India reported 8.8 million cases, and Japan accounted for approximately 3.9 million cases in 2023. This demographic shift, combined with rapid urbanization, is expected to drive significant market expansion in the Asia-Pacific region.
Key Biomarker Types: Safety and Efficacy
In 2023, the safety biomarkers segment held a dominant position in the global biomarkers market. These biomarkers indicate potential toxicity or adverse effects of a medicinal product or environmental contaminant. They are often utilized in early clinical trials, playing a crucial role in the decision-making process and advancing promising therapeutics from preclinical to clinical development.
On the other hand, the efficacy biomarkers segment is projected to experience the fastest growth in the forecast period. These biomarkers are indicators of a drug’s therapeutic effects and are crucial in evaluating the early stages of disease progression and pharmacological changes.
Cancer and Neurological Disorders Drive Disease-Specific Growth
The cancer segment dominated the biomarkers market in 2023. This dominance is attributed to the increasing incidence of cancer, its complex nature, and the rising demand for personalized medicines. Biomarkers play a key role in cancer diagnosis, prognosis, and predicting the likelihood of disease recurrence, independent of treatment, which has led to significant market demand.
Similarly, the neurological diseases segment is anticipated to grow at a considerable compound annual growth rate (CAGR) due to the rising incidence of age-related neurological disorders such as Alzheimer’s and Parkinson’s diseases. With an increasingly aging population, the demand for biomarkers in neurological disease research is expected to surge.
Drug Discovery and Development: The Leading Application
By application, the drug discovery and development segment held the dominant share of the global biomarkers market in 2023. Biomarkers provide valuable insights into disease pathways, assisting in the identification of new therapeutic targets. With increasing awareness and investments in drug discovery, this segment is expected to continue its growth trajectory in the coming years.
Notably, the Digital Biomarkers Summit, scheduled for May 2024, will bring industry leaders together to foster collaboration and accelerate the adoption of digital biomarkers. Rinol Alaj, Senior Director of Digital Health Technologies at Regeneron, emphasized the importance of collaboration in advancing the digital biomarkers field.
Recent Research Advancements
Innovative research in biomarkers continues to push the boundaries of medical science. In October 2024, researchers from the Walter and Eliza Hall Institute explored the potential of extracellular vesicles as biomarkers for cancer treatment. They discovered abnormally high levels of extracellular vesicles in the blood of mice with leukemia, suggesting new pathways for diagnostic and therapeutic applications.
In another significant breakthrough, researchers from Nationwide Children’s Hospital identified a potential biomarker for single ventricle heart disease (SVHD) in fetuses. By analyzing maternal blood samples, they found elevated levels of cell-free miRNAs in mothers carrying babies with SVHD, opening new avenues for early diagnosis.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biomarkers-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5322
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
